Cynthia A. Gauger, MD
Physician - Hematology/Oncology- Oncology
-
Male, C., Lensing, A. W. A., Palumbo, J. S., Kumar, R., Nurmeev, I., Hege, K., & EINSTEIN-Jr Phase 3 Investigators. (2020). Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. The Lancet Haematology, 7(1), e18-e27. doi:10.1016/S2352-3026(19)30219-4
-
Thom, K., Lensing, A. W. A., Nurmeev, I., Bajolle, F., Bonnet, D., Kenet, G., & EINSTEIN-Jr CVC-VTE investigators. (2020). Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE). Blood Advances, 4(19), 4632-4639. doi:10.1182/bloodadvances.2020002637
-
Sullivan, K. J., Dayan, J., Reichenbach, M., Irwin, M., Pitkin, A., Gauger, C., & Kissoon, N. (2017). Perioperative management of paediatric patients with sickle cell disease. West Indian Medical Journal, 66(4), 469-477. doi:10.7727/wimj.2017.135
-
Ware, R. E., Davis, B. R., Schultz, W. H., Brown, R. C., Aygun, B., Sarnaik, S., & Adams, R. J. (2016). Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia - TCD with Transfusions Changing to Hydroxyurea (TWiTCH): A multicentre, open-label, phase 3, non-inferiority trial. The Lancet, 387(10019), 661-670. doi:10.1016/S0140-6736(15)01041-7
-
Luchtman-Jones, L., Pressel, S., Hilliard, L., Brown, R. C., Smith, M. G., Thompson, A. A., & Ware, R. E. (2016). Effects of hydroxyurea treatment for patients with hemoglobin SC disease. American Journal of Hematology, 91(2), 238-242. doi:10.1002/ajh.24255